Procter & Gamble Health shares rally 19% after strong earnings; check all Q4 numbers

Procter & Gamble Health shares soared 18.5% to touch an intraday high of ₹6,700 apiece on Wednesday, May 27, a day after the company reported its March quarter earnings for the financial year 2025-26.

P&G Health's consolidated net profit jumped 56% to ₹95 crore in the fourth quarter of the fiscal year ending March 31, 2026 (Q4 FY26) as compared to ₹61 crore reported in the same period of the previous fiscal year. The growth in profit was led by superior brand-building activities and supported by strengthened supply chain and go-to-market capabilities, P&G Health said in a statement.

The Mumbai-based company's revenue from operations increased 19% on a year-on-year (YoY) basis to ₹370 crore in the January to March quarter as against ₹311 crore seen in Q4 FY25.

Its operating profit, also known as earnings before interest, taxes, depreciation, and amortisation (EBITDA), surged 67% to ₹135 crore as against ₹81 crore in the corresponding period last year. Its EBITDA margin expanded to 36.57% in contrast to 26.02% in the year-ago period.

During the quarter, the company delivered sales of ₹365 crore, up 20% compared to last year, driven by strong brand fundamentals and positive consumer response to new innovations.

P&G Health said it closed the 12-month financial year with reported sales of ₹1,385 crore and a profit after tax of ₹327 crore, reflecting growth of 16% and 30%, respectively, compared with the corresponding 12-month period from April 2024 to March 2025.

“We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities,” said Milind Thatte, Managing Director, Procter & Gamble Health.

Furthermore, P&G Health said its business continues to grow on the back of a strong pipeline of product innovations with a consumer-centric approach. 

P&G Health dividend

The board of directors of P&G Health also recommended a dividend of ₹45 per equity share (face value of ₹10 each) for the financial year ended March 31, 2026. The proposal is subject to approval by shareholders at the ensuing Annual General Meeting (AGM).

The company added that, if approved, the dividend will be paid on or before September 25, 2026.

P&G Health share price

At 10:59 AM, P&G Health shares were trading at ₹6,295 apiece on the National Stock Exchange, surging 11.37%. The stock is just 0.58% trading below its 52-week high of ₹6,739, hit on August 29, 2025.

Over a month’s time, the stock has climbed 22%, while it has jumped 9% in the last six months. From the beginning of the year, P&G Health shares have advanced 10%.

The company has a market capitalisation of ₹10,475.87 crore.